资讯
(UroToday.com) The 2025 APCCC Diagnostics annual meeting featured a session on how to diagnose prostate cancer and a presentation by Dr. Gerhardt Attard discussing molecular tests at diagnosis for ...
SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...
SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...
Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers poster session.
The Interdisciplinary Genitourinary Cancer Forum 2025, held between June 19 – 21, 2025 held in St. Petersburg, Florida, United States, was host to the Prostate Cancer Session 7: Non-metastatic ...
Neeraj Agarwal is joined by Wolfgang Fendler to discuss PSMA PET prognostication data. Dr. Fendler's international consortium of 50 sites analyzed 6,000 patients to develop risk stratification models ...
(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to a session on non-beta emitter PSMA radioligand therapy. Dr. David ...
ASCO GU 2025 STARLITE 2 trial in progress, nivolumab plus 177lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear ...
1 Attard, G., et al. (2025, May). Phase 3 AMPLITUDE trial: Niraparib and abiraterone acetate plus prednisone for metastatic castration-sensitive prostate cancer patients with alterations in homologous ...
Androgen receptor inhibition remains the mainstay treatment of advanced prostate cancer. However, therapeutic resistance to androgen receptor inhibition is almost universal. Prostate cancer cells can ...
SNMMI 2025, Prostate Cancer, Radioimmunotherapy Agent, CD46-Targeted Antibody-Drug Conjugate, CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer, ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果